Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL.
Yang DD, et al. Among authors: boldbaatar n.
Eur Urol Focus. 2019 Jan;5(1):69-76. doi: 10.1016/j.euf.2017.05.011. Epub 2017 Jun 17.
Eur Urol Focus. 2019.
PMID: 28753811